Western internal medicine is the best option to treat patients with diseases such as arthritis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, but it’s still a rare disease, according to a study published today in the journal Science Translational Medicine.
The study involved more than 60,000 adults and found that nearly two-thirds of people with chronic rheumatic diseases and arthritis who received medical care from a Western physician experienced some form of adverse side effect from the medicine.
“Our results provide a promising, if underappreciated, avenue for patients with chronic diseases and disorders,” said Dr. Richard Kwan, lead author of the study and director of the Western Internal Medicine Research Group at Brigham and Women’s Hospital.
“Our findings suggest that Western internal medical care may be a promising strategy for treating rheumatism and inflammatory bowel diseases.”
The researchers analyzed data from the National Health and Nutrition Examination Survey (NHANES), a nationally representative survey of the U.S. population that collects data on health conditions.
Researchers examined how many people with these diseases and conditions were receiving medical care at a hospital in each state.
They also looked at the outcomes of people who received care in the Western Medical Group, a medical group that is based in the Brigham and Woman’s Hospital in Boston, Massachusetts.
The results showed that Western medical care had no negative effects on the health of those who received treatment in the group, but the patients were more likely to experience side effects from the medication than those who did not receive it.
“The more people we had with rhema, the more likely we were to see adverse side effects,” Kwan said.
“When we got the people we saw with rhemus, they were the ones with rheimpah or rheminitis.
The more rheme they were, the less likely we’d see an adverse effect.”
In the study, which is one of the largest studies to date, researchers looked at data from 3,200 patients in the National Collaborating Center for Rheumatic Diseases and Allergies at the Brigham & Women’s Research Institute (BWHRI) in Boston.
Patients who received an annual fee of $500 for each care visit were included.
The study participants were divided into two groups: those who were in the BWHRI Rheumatology Clinical Center and those who had been treated in the hospital.
The researchers found that there were no statistically significant differences in the outcomes between the two groups, but patients who received Western medical treatment were more than twice as likely to have a complication from the treatment compared to patients who were not in the Rheumatics Clinical Center.
“In some ways, this study indicates that Western medicine may be more effective than traditional medicine for managing rheuma and rhemini,” said Kwan.
“We think that patients may be less likely to get side effects when they get care in a Western facility.”
The study was funded by the National Institutes of Health (grant R01AI104866), the National Center for Advancing Translating Science and Technology, the Office of National Drug Control Policy, and the National Institute on Aging.